Add comment in profyle t-a/b evidenceLevel data

bcgsc · Nov 6, 2023 · 40e7846 · 40e7846
1 parent 6bad258
commit 40e7846
Showing 1 changed file with 8 additions and 0 deletions.
diff --git a/data/evidenceLevels.json b/data/evidenceLevels.json
@@ -1187,13 +1187,15 @@
             "sourceId": "T2"
         },
         "profyle-t2a": {
+            "comment": "Not intended to be used in Statement",
             "description": "Biomarkers that predict response or resistance to therapies based on well-powered clinical trials in the same tumour type",
             "displayName": "PROFYLE T2A",
             "name": "PROFYLE Therapeutic Level 2A",
             "source": "profyle",
             "sourceId": "T2A"
         },
         "profyle-t2b": {
+            "comment": "Not intended to be used in Statement",
             "description": "Biomarkers that predict response or resistance to therapies based on well-powered clinical trials in another tumour type",
             "displayName": "PROFYLE T2B",
             "name": "PROFYLE Therapeutic Level 2B",
@@ -1218,13 +1220,15 @@
             "sourceId": "T3"
         },
         "profyle-t3a": {
+            "comment": "Not intended to be used in Statement",
             "description": "Biomarkers that predict response or resistance to therapies based on small series, case-reports, or that serve as inclusion criteria for a clinical trial, in the same tumour type",
             "displayName": "PROFYLE T3A",
             "name": "PROFYLE Therapeutic Level 3A",
             "source": "profyle",
             "sourceId": "T3A"
         },
         "profyle-t3b": {
+            "comment": "Not intended to be used in Statement",
             "description": "Biomarkers that predict response or resistance to therapies based on small series, case-reports, or that serve as inclusion criteria for a clinical trial, in another tumour type",
             "displayName": "PROFYLE T3B",
             "name": "PROFYLE Therapeutic Level 3B",
@@ -1249,13 +1253,15 @@
             "sourceId": "T4"
         },
         "profyle-t4a": {
+            "comment": "Not intended to be used in Statement",
             "description": "Biomarkers that show plausible therapeutic significance based on preclinical studies in the same tumour type",
             "displayName": "PROFYLE T4A",
             "name": "PROFYLE Therapeutic Level 4A",
             "source": "profyle",
             "sourceId": "T4A"
         },
         "profyle-t4b": {
+            "comment": "Not intended to be used in Statement",
             "description": "Biomarkers that show plausible therapeutic significance based on preclinical studies in another tumour type",
             "displayName": "PROFYLE T4B",
             "name": "PROFYLE Therapeutic Level 4B",
@@ -1280,13 +1286,15 @@
             "sourceId": "T5"
         },
         "profyle-t5a": {
+            "comment": "Not intended to be used in Statement",
             "description": "Novel biomarkers predicted to be oncogenic in therapeutically actionable genes, or evidence of activation of a therapeutically actionable pathway in the same tumour type",
             "displayName": "PROFYLE T5A",
             "name": "PROFYLE Therapeutic Level 5A",
             "source": "profyle",
             "sourceId": "T5A"
         },
         "profyle-t5b": {
+            "comment": "Not intended to be used in Statement",
             "description": "Novel biomarkers predicted to be oncogenic in therapeutically actionable genes, or evidence of activation of a therapeutically actionable pathway in another tumour type",
             "displayName": "PROFYLE T5B",
             "name": "PROFYLE Therapeutic Level 5B",